149 IN VITRO RELEASE OF EOSINOPHIL CATIONIC PROTEIN (ECP) FROM PERIPHERAL EOSINOPHILS REFLECTS DISEASE ACTIVITY IN CHILDHOOD INFLAMMATORY BOWEL DISEASE (IBD)

1996 ◽  
Vol 22 (4) ◽  
pp. 446
Author(s):  
W. Luck ◽  
B. Niggemann ◽  
U. Wahn ◽  
M. Becker
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
In Vitro Release ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein ◽  
Inflammatory Bowel ◽  
Vitro Release

scholarly journals Formation development and evaluation of microsphere of sulfasalazine for the treatment inflammatory bowel diseases

2021 ◽  
Vol 11 (5-S) ◽  
pp. 124-127
Author(s):  
Tanu Tiwari ◽  
Vivek Jain ◽  
Sunil Kumar Jain ◽  
Pushpendra Kumar Khangar
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
In Vitro Release ◽  
Entrapment Efficiency ◽  
Inflammatory Disorder ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Vitro Release ◽  
Polymer Ratio

Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disorder of the small intestine and colon. IBD includes ulcerative colitis (UC) and Crohn’s disease (CD), and it is a main reason for the expansion of colon cancer, referred to as colitis-associated cancer (CAC). Oral colon-targeted microsphere based drug delivery system containing sulfasalazine was prepared, optimized and characterized. The microspheres were effectively prepared by simple emulsification phase-separation technique followed by cross-linking. The formulations were optimized on the basis of drug: polymer ratio, stirring speed, concentration of glutaraldehyde. The prepared microspheres were characterized on the basis of morphology, entrapment efficiency, particle size and in-vitro release. Keywords: Microspheres, Sulfasalazine, Inflammatory bowel disease, Colon-targeted, Chitosan

scholarly journals Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease

2019 ◽  
Vol 8 (12) ◽  
pp. 2025 ◽  
Author(s):  
Nada Abedin ◽  
Teresa Seemann ◽  
Sandra Kleinfeld ◽  
Jessica Ruehrup ◽  
Stefani Röseler ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Food Allergy ◽  
Bowel Disease ◽  
Eosinophil Cationic Protein ◽  
Young Patients ◽  
Area Under The Curve ◽  
Predictive Biomarker ◽  
Fecal Calprotectin ◽  
Cationic Protein ◽  
Inflammatory Bowel

Background and Aims: Fecal biomarkers are important non-invasive markers monitoring disease activity in inflammatory bowel disease (IBD). We compared the significance of fecal eosinophil cationic protein (fECP) and fecal calprotectin (fCal). Methods: fECP and fCal were measured in patients with Crohn’s disease (CD, n = 97), ulcerative colitis (UC, n = 53), Clostridioides difficile infection (CDI, n = 9), primary food allergy (PFA, n = 11), pollen-associated food allergy (n = 25) and non-inflammatory controls (n = 78). Results were correlated with clinical and endoscopic IBD activity scores. Results: fECP was significantly elevated in CD, UC, CDI and PFA compared to controls. fCal was significantly increased in CD, UC and CDI. fECP had lower diagnostic accuracy than fCal (area under the curve (AUC) = 0.88) in differentiating between endoscopically active and inactive patients with IBD (AUC = 0.77, ROC analysis). In contrast to fCal, fECP correlated negatively with age and levels were also elevated in clinically and endoscopically inactive patients with IBD <45 years (endoscopically inactive IBD vs controls; AUC for fECP = 0.86; AUC for fCal = 0.62). However, in those patients with low inflammatory activity (fCal <250 mg/kg), high fECP indicated the need for treatment modification or surgery (fECP <200 µg/kg = 22%; 200–600 µg/kg = 44%; >600 µg/kg = 82%) at month 48 of follow-up. Conclusions: fECP is a diagnostic and prognostic marker in young patients with IBD in remission.

Localization and Activity of Inflammatory Bowel Disease Using 111ln Leukocyte Imaging

1988 ◽  
Vol 27 (03) ◽  
pp. 83-86 ◽  
Author(s):  
B. Briele ◽  
F. Wolf ◽  
H. J. Biersack ◽  
F. F. Knapp ◽  
A. Hotze
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Cell Uptake ◽  
Disease Extent ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Leukocyte Imaging

A prospective study was initiated to compare the clinically proven results concerning localization/extent and activity of inflammatory bowel diseases with those of 111ln-oxine leukocyte imaging. All patients studied were completely examined with barium enema x-ray, clinical and laboratory investigations, and endoscopy with histopathology. A total of 31 leukocyte scans were performed in 15 patients (12 with Crohn’s disease, 3 with ulcerative colitis). The scans were graded by comparing the cell uptake of a lesion (when present) and a bone marrow area providing a count ratio (CR). The inflammatory lesions were correctly localized on 26 leukocyte scans, and in 21 scans the scintigraphically estimated extent of disease was identical to endoscopy. In 5 cases the disease extent was underestimated, 4 scans in patients with relapse of Crohn’s disease were falsely negative, and in one patient with remission truly negative. The scintigraphically assessed disease activity was also in a good agreement with clinical disease activity based on histopathology in all cases. We conclude that leukocyte imaging provides valuable information about localization and activity of inflammatory bowel disease.

Sign in / Sign up

Export Citation Format

Share Document